Treatments for Neuropathy

Abstract

Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.

1 - 20 . (canceled) 
     
     
         21 . A method of treating a small fiber peripheral neuropathy in a person determined to be in need thereof comprising:
 topically administering to the person an anti-peripheral neuropathic quinoline compound of the formula:   
       
         
           
           
               
               
           
         
         wherein R 1 -R 7  are each independently H, hydroxy, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted amine, substituted or unsubstituted alkylamine, substituted or unsubstituted dialkylamine, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         22 . The method of  claim 21 , wherein the compound has a formula/name of Table 1, Table 2 Table 3. 
     
     
         25 . The method of  claim 21 , wherein compound is administered in a lotion at 1.2 mM, and the lotion further comprises N-methyl-pyrrolidone (5%), isopropyl myristate (5%) and petroleum jelly (90%). 
     
     
         28 . The method of  claim 21  further comprising the antecedent step determining that the person is in need of said method by detecting the small fiber neuropathy in the person. 
     
     
         29 . The method of  claim 21  further comprising the subsequent step of detecting a resultant diminution of the small fiber neuropathy. 
     
     
         30 . The method of  claim 21  further comprising the antecedent step determining that the person is in need of said method by detecting the small fiber neuropathy in the person, and the subsequent step of detecting a resultant diminution of the small fiber neuropathy. 
     
     
         31 . A method of treating a small fiber peripheral neuropathy in a person determined to be in need thereof comprising:
 topically administering to the person an agonist of glial cell-derived neurotrophic factor (GDNF) receptor GFRα1 or GFRα2, under conditions effective to treat the peripheral neuropathy in the person.   
     
     
         32 . The method of  claim 31 , wherein the agonist has a formula/name of Table 1, Table 2 Table 3. 
     
     
         35 . The method of  claim 31 , wherein compound is administered in a lotion at 1.2 mM, and the lotion further comprises N-methyl-pyrrolidone (5%), isopropyl myristate (5%) and petroleum jelly (90%). 
     
     
         38 . The method of  claim 31  further comprising the antecedent step determining that the person is in need of said method by detecting the small fiber neuropathy in the person, and the subsequent step of detecting a resultant diminution of the small fiber neuropathy. 
     
     
         39 . A topical lotion comprising an anti-peripheral neuropathic effective amount of an anti-peripheral neuropathic quinoline compound having a formula/name of Table 1, Table 2 Table 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier formulated for topical application. 
     
     
         40 . The lotion of  claim 39  containing the compound at 1.2 mM, and further comprising N-methyl-pyrrolidone (5%), isopropyl myristate (5%) and petroleum jelly (90%).